October 2, 2024 – Talk Bio

Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), Erleada (Apalutamide), Xtandi (Enzalutamide), Real-World Study, Comparative Efficacy, Safety Profiles

FDA Panel Recommends Limiting Immunotherapy Access for Stomach and Esophageal Cancer Patients Based on PD-L1 Expression

7 months ago talkbio0Tagged Esophageal Neoplasms, Gene Expression, Immunotherapy, Keytruda, Malignant neoplasm of stomach, PD-L1, Tevimbra, United States Food and Drug Administration

FDA, Immunotherapy, Stomach Cancer, Esophageal Cancer, PD-L1 Expression, Keytruda, Opdivo, Tevimbra

GE HealthCare’s Flyrcado (flurpiridaz F 18) PET Radiotracer Receives FDA Approval for Enhanced Detection of Coronary Artery Disease

7 months ago talkbio0Tagged Approved, Cardiac imaging, Coronary Arteriosclerosis, F 18, Flyrcado, Health care facility, nuclear cardiology, Pet Animal, Radiotracers, United States Food and Drug Administration

GE HealthCare, Flyrcado, flurpiridaz F 18, PET radiotracer, Coronary artery disease (CAD), FDA approval, Cardiac imaging, Nuclear cardiology

Big Pharma’s Layoff Wave Continues in New Jersey: J&J and Bayer Announce Significant Job Cuts

7 months ago talkbio0Tagged Bayer, Big Pharma layoffs, Drug Industry, Johnson & Johnson, New Jersey, restructuring

Big Pharma layoffs, New Jersey, Johnson & Johnson, Bayer, pharmaceutical industry restructuring

Remedee Labs Secures European Approval for Groundbreaking Fibromyalgia Wristband Therapy

7 months ago talkbio0Tagged Approved, endorphin stimulation, European (ethnic group), Fibromyalgia, millimeter-wave technology, Non-Pharmaceutical, Remedee Labs, wristband therapy

Remedee Labs, fibromyalgia, wristband therapy, European approval, non-pharmaceutical treatment, millimeter-wave technology, endorphin stimulation

Amgen Faces Investor Lawsuit Over $10.7 Billion Tax Liability

7 months ago talkbio0Tagged amgen, investor, Legal

Amgen, investor lawsuit, tax liability, $10.7 billion, legal challenge

IGM Biosciences Undergoes Strategic Pivot to Autoimmune Diseases, Overhauls Leadership and Reduces Workforce

7 months ago talkbio0Tagged Autoimmune Diseases, Biosciences, Changing, Immunoglobulin M, imvotamab, Leadership, strategic pivot, T cell-engaging IgM antibodies

IGM Biosciences, autoimmune diseases, strategic pivot, T cell-engaging IgM antibodies, leadership changes, workforce reduction, imvotamab, IGM-2644